Incyte‘s and Eli Lilly’s Janus kinase (JAK) 1/2 inhibitors, Jakafi (ruxolitinib) and Olumiant (baricitinib) could have a mechanism edge over Pfizer’s JAK 1/3 inhibitor Xeljanz (tofacitinib) in Covid-19. Theravance Biopharma’s pan-JAK inhibitor TD-0903 is distinct for its nebulised method of administration, but there is still scepticism of its benefit.

Jakafi and Olumiant could provide a more precise link to downregulating interleukin (IL)-6 to mitigate cytokine storm syndrome (CSS) seen in Covid-19 associated with Xeljanz. Read more here.